Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 16/20 | 0.57 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | F11 | P03951 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21437609 | 0.91 | CFD (0.69) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL31090095 | 0.91 | CFD (0.69) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL23217218 | 0.89 | CFD (0.72) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL21438544 | 0.86 | CFD (0.62) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL21438250 | 0.85 | CFD (0.78) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL23217635 | 0.85 | CFD (0.60) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL21437517 | 0.84 | CFD (0.65) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL23218035 | 0.84 | CFD (0.52) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL29853046 | 0.84 | CFD (0.52) | CFDPLAUPLGF11KLKB1 | |
| SCHEMBL23217614 | 0.84 | TBXAS1 (0.44) | CFDTBXAS1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041717-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-08-17 | — | — | EP | disclosed |
| CN-114555570-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021072156-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |